CVE:NXGNexgenRx Stock Price, Forecast & News

C$0.18

0.00 (0.00 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

C$0.18

Now: C$0.18▼

C$0.18

50-Day Range

C$0.15

MA: C$0.17▼

C$0.20

52-Week Range

C$0.15

Now: C$0.18▼

C$0.33

Volume94,140 shs

Average Volume31,245 shs

Market CapitalizationC$12.24 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans in Canada. It offers prescription drug claims; dental claims; and claims for extended health benefits, as well as provides a health care spending account that offers an amount of money to an individual to pay for health or dental benefits. The company also provides individual and aggregate stop loss products; medical emergency and travel assistance insurance services; administrative services, including the collection and payment of premiums for life and LTD coverage, as well as a suite of reporting tools; Web claims submission services; and direct deposit services. In addition, it offers ancillary services. NexgenRx Inc. was founded in 2003 and is headquartered in Toronto, Canada.

Beat the Market (BTM) Rank^™

3.0 Analyst's Opinion

Consensus Rating
NexgenRx has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of C$4.00, NexgenRx has a potential upside of 2,185.7% from its current price of C$0.18.
Amount of Analyst Coverage
NexgenRx has received no research coverage in the past 90 days.

2.2 Community Rank

Outperform Votes
NexgenRx has received 54 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
NexgenRx has received 69 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
NexgenRx has received 56.10% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about NexgenRx and other stocks. Vote “Outperform” if you believe NXG will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NXG will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
NexgenRx does not currently pay a dividend.
Dividend Growth
NexgenRx does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NexgenRx insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of NexgenRx is -60.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of NexgenRx is -60.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
NexgenRx has a P/B Ratio of 5.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.04 out of 5 stars

Industry, Sector and Symbol

Stock Exchange CVE

Industry Health Care Plans

Sub-IndustryN/A

SectorMedical

Current SymbolCVE:NXG

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.nexgenrx.com

Phone+1-416-6953393

Debt

Debt-to-Equity Ratio184.36

Current Ratio0.84

Quick Ratio0.06

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesC$10.03 million

Price / Sales1.22

Cash FlowC$0.01 per share

Price / Cash Flow18.00

Book ValueC$0.03 per share

Price / Book5.65

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

EmployeesN/A

Outstanding Shares69,919,000

Market CapC$12.24 million

Next Earnings DateN/A

OptionableNot Optionable

Receive NXG News and Ratings via Email

Sign-up to receive the latest news and ratings for NXG and its competitors with MarketBeat's FREE daily newsletter.

NexgenRx (CVE:NXG) Frequently Asked Questions

How has NexgenRx's stock been impacted by COVID-19 (Coronavirus)?

NexgenRx's stock was trading at C$0.18 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NXG shares have decreased by 2.8% and is now trading at C$0.18. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of NexgenRx?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NexgenRx in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for NexgenRx.

What price target have analysts set for NXG?

1 equities research analysts have issued 12 month target prices for NexgenRx's stock. Their forecasts range from C$4.00 to C$4.00. On average, they anticipate NexgenRx's share price to reach C$4.00 in the next year. This suggests a possible upside of 2,185.7% from the stock's current price. View analysts' price targets for NexgenRx.

Has NexgenRx been receiving favorable news coverage?

News headlines about NXG stock have trended very positive this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NexgenRx earned a news impact score of 4.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an effect on the company's share price in the next several days. View the latest news aboutNexgenRx.

Who are some of NexgenRx's key competitors?

Some companies that are related to NexgenRx include Zivo Bioscience (ZIVO), Zelda Therapeutics (ZLD), CNS Pharmaceuticals (CNSP), Q BioMed (QBIO), HTG Molecular Diagnostics (HTGM), cbdMD (YCBD), Invion (IVX), Guardion Health Sciences (GHSI), Acerus Pharmaceuticals (ASPCF), IMMUTEP LTD/S (IMMP), NanoViricides (NNVC), Polarean Imaging (POLX), Bellicum Pharmaceuticals (BLCM), Millendo Therapeutics (MLND) and Lipocine (LPCN). View all competitors.

What other stocks do shareholders of NexgenRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NexgenRx investors own include WestJet Airlines (WJA) and Hydro One (H).

Who are NexgenRx's key executives?

NexgenRx's management team includes the following people:

Mr. Ronald C. Loucks, Founder, CEO, Pres & Director (Age 69)
Mr. Kelly Elher, Chief Financial Officer
Ms. Liliana Martino, National VP of Sales
Mr. Andrew Munroe, Director of Operations
Mr. Hugh C. Hart, VP of Sales & Account Management

What is NexgenRx's stock symbol?

NexgenRx trades on the Canadian Venture Exchange (CVE) under the ticker symbol "NXG."

How do I buy shares of NexgenRx?

Shares of NXG and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is NexgenRx's stock price today?

One share of NXG stock can currently be purchased for approximately C$0.18.

How big of a company is NexgenRx?

NexgenRx has a market capitalization of C$12.24 million and generates C$10.03 million in revenue each year.

What is NexgenRx's official website?

The official website for NexgenRx is www.nexgenrx.com.

How can I contact NexgenRx?

NexgenRx's mailing address is 185 the West Mall Suite 600, ETOBICOKE, ON M9C 5L5, Canada. The company can be reached via phone at +1-416-6953393.

This page was last updated on 6/5/2020 by MarketBeat.com Staff